New genetic variant that might improve warfarin dose prediction in African Americans by Schelleman Hedi, Brensinger Colleen M, Chen Jinbo, Finkelman Brian S, Rieder Mark J, Kimmel Stephen E in British journal of clinical pharmacology (2010). PubMed

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Variants in the CYP2C9 (i.e. *2 and *3) and VKORC1 (i.e. 1173C/T or -1639G/A) genes have been shown to influence warfarin dose requirements. However, these factors seem to explain less of the dose variability in African Americans who have a lower prevalence of the CYP2C9*2 and *3 and VKORC1 1173T alleles.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.